Increased Tissue Penetration of Doxorubicin in Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) after High-Intensity Ultrasound (HIUS)

被引:9
|
作者
Khosrawipour, Veria [1 ]
Reinhard, Soren [2 ]
Martino, Alice [1 ]
Khosrawipour, Tanja [1 ,3 ]
Arafkas, Mohamed [4 ]
Mikolajczyk, Agata [5 ]
机构
[1] Univ Calif Irvine, Dept Surg, Div Colorectal Surg, Irvine, CA 92717 USA
[2] Univ Calif Berkeley, Dept Bioengn, Oakland, CA USA
[3] Univ Hosp Dusseldorf, Dept Surg, Dusseldorf, North Rhein Wes, Germany
[4] Orthoklin Dortmund, Dept Plast Surg, Dusseldorf, North Rhein Wes, Germany
[5] Wroclaw Univ Environm & Life Sci, Dept Biochem & Mol Biol, Fac Vet Med, Wroclaw, Lower Silesia, Poland
关键词
FOCUSED ULTRASOUND; DISTRIBUTION PATTERN; CANCER; DEPTH; PROLIFERATION; IRRADIATION; RATIONALE; CARCINOMA;
D O I
10.1155/2019/6185313
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. High-intensity ultrasound (HIUS) has been studied for the past two decades as a new therapeutic option for solid tumor direct treatment and a method for better chemotherapy delivery and perfusion. This treatment approach has not been tested to our knowledge in peritoneal metastatic therapy, where limited tissue penetration of intraperitoneal chemotherapy has been a main problem. Both liquid instillations and pressurized aerosols are affected by this limitation. This study was performed to evaluate whether HIUS improves chemotherapy penetration rates. Methods. High-intensity ultrasound (HIUS) was applied for 0, 5, 30, 60, 120, and 300 seconds on the peritoneal tissue samples from fresh postmortem swine. Samples were then treated with doxorubicin via pressurized intraperitoneal aerosol chemotherapy (PIPAC) under 12 mmHg and 37 degrees C temperature. Tissue penetration of doxorubicin was measured using fluorescence microscopy on frozen thin sections. Results. Macroscopic structural changes, identified by swelling of the superficial layer of the peritoneal surface, were observed after 120 seconds of HIUS. Maximum doxorubicin penetration was significantly higher in peritoneum treated with HIUS for 300 seconds, with a depth of 962.88 +/- 161.4 mu m (p < 0.05). Samples without HIUS had a penetration depth of 252.25 +/- 60.41. Tissue penetration was significantly increased with longer HIUS duration, with up to 3.8-fold increased penetration after 300 sec of HIUS treatment. Conclusion. Our data indicate that HIUS may be used as a method to prepare the peritoneal tissue for intraperitoneal chemotherapy. Higher tissue penetration rates can be achieved without increasing chemotherapy concentrations and preventing structural damage to tissue using short time intervals. More studies need to be performed to analyze the effect of HIUS in combination with intraperitoneal chemotherapy.
引用
收藏
页数:6
相关论文
共 50 条
  • [31] Activity of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: Preliminary clinical experience
    Tempfer, Clemens B.
    Celik, Ilknur
    Solass, Wiebke
    Buerkle, Bernd
    Pabst, Urs G.
    Zieren, Juergen
    Strumberg, Dirk
    Reymond, Marc-Andre
    [J]. GYNECOLOGIC ONCOLOGY, 2014, 132 (02) : 307 - 311
  • [32] Numerical modeling of high-intensity focused ultrasound-mediated intraperitoneal delivery of thermosensitive liposomal doxorubicin for cancer chemotherapy
    Rezaeian, Mohsen
    Sedaghatkish, Amir
    Soltani, M.
    [J]. DRUG DELIVERY, 2019, 26 (01): : 898 - 917
  • [33] How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures
    Giger-Pabst, Urs
    Tempfer, Clemens B.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2018, 22 (12) : 2187 - 2193
  • [34] How to Perform Safe and Technically Optimized Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC): Experience After a Consecutive Series of 1200 Procedures
    Urs Giger-Pabst
    Clemens B. Tempfer
    [J]. Journal of Gastrointestinal Surgery, 2018, 22 : 2187 - 2193
  • [35] Palliative systemic chemotherapy with or without pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin (PIPAC C/D) for gastric cancer with peritoneal metastasis: A propensity score analysis.
    Khomiakov, Vladimir
    Meisner, Christoph
    Ryabov, Andrey
    Bolotina, Larisa
    Utkina, Anna
    Kolobaev, Ilia
    Sobolev, Dmitry
    Chayka, Anna
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [36] Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey
    M. Graversen
    S. Detlefsen
    P. Pfeiffer
    L. Lundell
    M. B. Mortensen
    [J]. Clinical & Experimental Metastasis, 2018, 35 : 103 - 108
  • [37] Severe peritoneal sclerosis after repeated pressurized intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC OX): report of two cases and literature survey
    Graversen, M.
    Detlefsen, S.
    Pfeiffer, P.
    Lundell, L.
    Mortensen, M. B.
    [J]. CLINICAL & EXPERIMENTAL METASTASIS, 2018, 35 (03) : 103 - 108
  • [38] Enabling Microparticle Imprinting to Achieve Penetration and Local Endurance in the Peritoneum via High-Intensity Ultrasound (HIUS) for the Treatment of Peritoneal Metastasis
    Mikolajczyk, Agata
    Khosrawipour, Tanja
    Martino, Alice
    Kulas, Joanna
    Pieczka, Marek
    Zacharski, Maciej
    Nicpon, Jakub
    Khosrawipour, Veria
    [J]. INTERNATIONAL JOURNAL OF SURGICAL ONCOLOGY, 2020, 2020
  • [39] Pressurized intraperitoneal aerosol chemotherapy with low-dose cisplatin and doxorubicin (PIPAC C/D) in patients with gastric cancer and peritoneal metastasis: a phase II study
    Struller, Florian
    Horvath, Philipp
    Solass, Wiebke
    Weinreich, Frank-Juergen
    Strumberg, Dirk
    Kokkalis, Marios K.
    Fischer, Imma
    Meisner, Christoph
    Koenigsrainer, Alfred
    Reymond, Marc A.
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [40] Pressurized Intraperitoneal Aerosol Chemotherapy with Low-Dose Cisplatin and Doxorubicin (PIPAC C/D) in Patients with Gastric Cancer and Peritoneal Metastasis: a Phase-II trial (PIPAC-GA1)
    Struller, F.
    Solass, W.
    Horvath, P.
    Weinreich, F.
    Strumberg, D.
    Koenigsrainer, A.
    Reymond, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 63 - 63